E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis

C B Vos, A M Cleton-Jansen, G Berx, W J de Leeuw, N T ter Haar, F van Roy, C J Cornelisse, J L Peterse, M J van de Vijver, C B Vos, A M Cleton-Jansen, G Berx, W J de Leeuw, N T ter Haar, F van Roy, C J Cornelisse, J L Peterse, M J van de Vijver

Abstract

In breast cancer, inactivating point mutations in the E-cadherin gene are frequently found in invasive lobular carcinoma (ILC) but never in invasive ductal carcinoma (IDC). Lobular carcinoma in situ (LCIS) adjacent to ILC has previously been shown to lack E-cadherin expression, but whether LCIS without adjacent invasive carcinoma also lacks E-cadherin expression and whether the gene mutations present in ILC are already present in LCIS is not known. We report here that E-cadherin expression is absent in six cases of LCIS and present in 150 cases of ductal carcinoma in situ (DCIS), both without an adjacent invasive component. Furthermore, using mutation analysis, we could demonstrate the presence of the same truncating mutations and loss of heterozygosity (LOH) of the wild-type E-cadherin in the LCIS component and in the adjacent ILC. Our results indicate that E-cadherin is a very early target gene in lobular breast carcinogenesis and plays a tumour-suppressive role, additional to the previously suggested invasion-suppressive role.

References

    1. Science. 1991 Mar 22;251(5000):1451-5
    1. J Cell Biol. 1991 Apr;113(1):173-85
    1. Cell. 1991 Jul 12;66(1):107-19
    1. J Pathol. 1993 Feb;169(2):245-50
    1. Am J Pathol. 1993 Apr;142(4):987-93
    1. Oncogene. 1996 Nov 7;13(9):1919-25
    1. Jpn J Cancer Res. 1994 Oct;85(10):1035-9
    1. Am J Pathol. 1994 Dec;145(6):1301-8
    1. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416-9
    1. Cancer Res. 1995 Nov 15;55(22):5195-9
    1. EMBO J. 1995 Dec 15;14(24):6107-15
    1. Am J Pathol. 1993 Dec;143(6):1731-42

Source: PubMed

3
Prenumerera